Dupilumab is a monoclonal antibody used in the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. It works by blocking the action of certain proteins in the body that cause inflammation and is typically administered via subcutaneous injection. Research on dupilumab includes studies on its efficacy in managing these conditions, its safety profile, and potential long-term effects. Ongoing research is also investigating its use in other allergic and inflammatory conditions.